Literature DB >> 24144951

Targeted gene delivery to glioblastoma using a C-end rule RGERPPR peptide-functionalised polyethylenimine complex.

Jing Wang1, Yang Lei, Cao Xie, Weiyue Lu, Zhiqiang Yan, Jie Gao, Zuoxu Xie, Xiaoyu Zhang, Min Liu.   

Abstract

Safe and efficient systems capable of specifically targeting brain tumour cells represent a promising approach for the treatment glioblastoma multiforme. Neuropilin-1 (NRP-1) is over-expressed in U87 glioma cells. In the current study, the tumour specific peptide RGERPPR, which binds specifically to NRP-1, was used as a targeting ligand in a gene delivery strategy for glioblastoma. The RGERPPR peptide was coupled to branched polyethylenimine (PEI, 25kDa) using heterobifunctional Mal-PEG-NHS, resulting in a novel gene delivery polymer. Polymer/plasmid DNA (pDNA) complexes were formed and their sizes and zeta potentials were measured. Compared with the unmodified mPEG-PEI/pDNA complexes, the RGERPPR-PEG-PEI/pDNA complex led to a significant enhancement in intracellular gene uptake and tumour spheroid penetration. Furthermore, the RGERPPR-PEG-PEI/pDNA complex facilitated enhanced transfection efficiency levels, as well as a reduction in cytotoxicity when tested in U87 glioma cells in vitro. Most significantly of all, when complexes formed with pDsRED-N1 were injected into the tail vein of intracranial U87 tumour-bearing nude mice, the RGERPPR-PEG-PEI complexes led to improved levels of red fluorescence protein expression in the brain tissue. Taken together, the results show that RGERPPR-PEG-PEI could be used as a safe and efficient gene delivery vehicle with potential applications in glioblastoma gene delivery.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-end rule peptide; Gene delivery; Glioma targeting; Neuropilin-1; Polyethylenimine

Mesh:

Substances:

Year:  2013        PMID: 24144951     DOI: 10.1016/j.ijpharm.2013.10.017

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Peptide GE11-Polyethylene Glycol-Polyethylenimine for targeted gene delivery in laryngeal cancer.

Authors:  Henglei Ren; Liang Zhou; Min Liu; Weiyue Lu; Chunli Gao
Journal:  Med Oncol       Date:  2015-05-26       Impact factor: 3.064

Review 2.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 3.  Polymer-mediated gene therapy: Recent advances and merging of delivery techniques.

Authors:  Janelle W Salameh; Le Zhou; Sarah M Ward; Cristiam F Santa Chalarca; Todd Emrick; Marxa L Figueiredo
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-12-02

Review 4.  Progress and perspectives on targeting nanoparticles for brain drug delivery.

Authors:  Huile Gao
Journal:  Acta Pharm Sin B       Date:  2016-06-14       Impact factor: 11.413

5.  Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics.

Authors:  Lipeng Gao; Jing Yu; Yang Liu; Jinge Zhou; Lei Sun; Jing Wang; Jianzhong Zhu; Hui Peng; Weiyue Lu; Lei Yu; Zhiqiang Yan; Yiting Wang
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

Review 6.  Long Noncoding RNA (lncRNA)-Mediated Competing Endogenous RNA Networks Provide Novel Potential Biomarkers and Therapeutic Targets for Colorectal Cancer.

Authors:  Liye Wang; Kwang Bog Cho; Yan Li; Gabriel Tao; Zuoxu Xie; Bin Guo
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

Review 7.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

8.  Downregulation of ROCK2 through nanocomplex sensitizes the cytotoxic effect of temozolomide in U251 glioma cells.

Authors:  Xiaojun Wen; Amin Huang; Zhonglin Liu; Yunyun Liu; Jingyang Hu; Jun Liu; Xintao Shuai
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.